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ABSTRACT The list of ADCs in the clinic continues to grow,
bolstered by the success of first two marketed ADCs: ADCE
TRIS® and Kadcyla®. Currently, there are 40 ADCs in various
phases of clinical development. However, only 34 of these have
published their structures. Of the 34 disclosed structures, 24 of
them use a linkage to the thiol of cysteines on the monoclonal
antibody. The remaining 10 candidates utilize chemistry to surface
lysines of the antibody. Due to the inherent heterogeneity of
conjugation to the multiple lysines or cysteines found in mAbs,
significant research efforts are now being directed toward the
production of discrete, homogeneous ADC products, via site-
specific conjugation. These site-specific conjugations may involve
genetic engineering of the mAb to introduce discrete, available
cysteines or non-natural amino acids with an orthogonally-
reactive functional group handle such as an aldehyde, ketone,
azido, or alkynyl tag. These site-specific approaches not only in-
crease the homogeneity of ADCs but also enable novel bio-
orthogonal chemistries that utilize reactive moieties other than
thiol or amine. This broadens the diversity of linkers that can be
utilized which will lead to better linker design in future generations
of ADCs.
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ALL Acute lymphoblastic leukemia
AML Acute myeloid leukemia
BTG Bacterial transglutaminase











FGE Formylglycine generating enzyme
mc Maleimidocaproyl
mcc Maleimidomethyl cyclohexane-1-
carboxylate, linked to cysteine of mAb
MCC Maleimidomethyl cyclohexane-1-




MMAE Monomethyl auristatin E
MMAF Monomethyl auristatin F
NHL Non-Hodgkin lymphoma
NHS N-hydroxy succinimide
nnAA Non-natural amino acid
NSCLC Non small-cell lung carcinoma
PABC Para-aminobenzyloxycarbonyl
PBD Pyrrolo[2,1-c][1,4]benzodiazepine
RCC Renal cell carcinoma
SC Squamous cell
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Current antibody-drug conjugates (ADC) are approaching
the realization of the magic bullet theory first proposed by
Paul Ehrlich over a century ago, in which he reasoned that
if a compound could be made that selectively targeted a
disease-causing organism, then a toxin for that organism could
be delivered along with the agent of selectivity (1). In its sim-
plest form, ADCs are comprised of an antibody to which is
attached a cytotoxic agent through a linker (Fig. 1). The anti-
bodies are generally fully humanized monoclonal antibodies
(mAbs) which have high selectivity for tumor-associated anti-
gens, long circulating half-lives, and little to no immunogenic-
ity. Thus, mAbs provide an ideal delivery platform for selec-
tive targeting of tumor cells. If combined with cytotoxic agents
that can be released within the tumor cells once they have
been delivered by the selective antibodies, then the eradica-
tion of the tumor cell can be realized while sparing normal
cells which have not been targeted by the antibody—thus
providing a magic bullet. However, the realization of this the-
ory has taken decades to implement and is still a work in
progress.
The mechanism of action of a successful ADC is depicted
in Fig. 2. After being introduced into the plasma (step 1), the
ADC recognizes an antigen on the cell surface (step 2). The
ADC-antigen complex then undergoes endocytosis, termed
internalization (step 3). Once inside the tumor cell, the
ADC-antigen complex is fused with the endosome which
breaks up the complex for antigen recycling and transports
the ADC to the lysosome. Finally, the ADC undergoes various
lysosomal degradations to release the cytotoxic drug (step 4),
which then binds to its target. The majority of payloads cause
cell death or apoptosis via either DNA intercalation or
through binding to microtubulins (step 5). Thus, the ideal
tumor antigen must be localized on the cell surface in order
to allow efficient ADC binding. In addition, the antigen
should demonstrate restricted expression on tumor cells, i.e.,
the antigen should be predominately expressed on tumor cells
with minimal expression on normal cells. An important factor
for the therapeutic index is the antigen density since a small
number of antigenic sites would pose a problem for efficient
ADC targeting, internalization and delivery. It has been esti-
mated that the delivery of a lethal quantity of a tubulin-acting
payload into a tumor cell may be difficult to achieve below
~10,000 antigen proteins per cell (2). For the antibody, it must
be able to bind to tumor-associated antigens with high speci-
ficity and high affinity. In addition, the antibody should be
non-immunogenic, an issue that has been minimized with
chimeric and fully-humanized monoclonal antibodies (3).
The ideal payload, or cytotoxin, needs to have high potency
against the specific tumor type since it has been estimated that
only 1–2% of the administered drug reached the intracellular
target (e.g., tumoral DNA or microtubules) (4). The tubulin-
binding cytotoxins, such as the maytansinoids or the
auristatins, have in vitro cytotoxic potencies in the picomolar
range (10−12 M). What has become clear is that every com-
ponent of an ADC must be optimized in order to fully realize
the goal of a targeted therapy with improved efficacy and
tolerability.
Recently, there has been a great deal of discussion in the
literature regarding ADCs, much of which has focused on the
biological characteristics of this class of therapeutics (5–7).
However, the focus of this review is from a chemistry perspec-
tive of the linker.
THE LINKER
The linker, which is the highlight of this review, needs to
possess a number of key attributes, including the requirement
to be stable in plasma after drug administration for an extend-
ed period of time such that the ADC can localize to tumor
cells. This stability prevents the premature release of the cyto-
toxic payload, which would indiscriminately damage tissue of
all kinds, thereby lowering the therapeutic index of the ADC.
Upon internalization, the ADC should liberate the payload
such that the payload can bind to its target. In addition to
these two basic functions, linkers can have a profound effect
on the physico-chemical properties of the ADC. In particular,
most of the cytotoxic payloads are hydrophobic in nature.
Thus, linking them to the mAb with an additional hydropho-
bic moiety can create problems due to aggregation. ADC
Fig. 1 Schematic of an ADC containing an antibody onto which is covalently
attached a linker which in turn is covalently attached to a cytotoxin.
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aggregates are insoluble and often limit achievable drug loading
onto the antibody. It has been conjectured that ADC aggregates
are sequestered in the liver, leading to hepatotoxicity (8). Lastly,
protein aggregation of biologics, in general, has been linked to
increased immunogenicity (9). Due to these safety concerns, ag-
gregation needs to be monitored over time in ADC products to
establish a safe shelf-life. In addition to aggregation problems, the
hydrophobic characteristic of the majority of cytotoxic com-
pounds in ADCs causes them to be good substrates formultidrug
resistance (MDR) transporters. These transporters are responsi-
ble for effluxing cytotoxins out of the tumor cells, thus
compromising efficacy. However, Kovtun et al. has shown that
using a hydrophilic linker with maytansinoids produced a hydro-
philic metabolite of DM1 which was not anMDR substrate (10).
This hydrophilic-linked DM1ADCwasmarkedlymore effective
in an MDR-1-expressing human xenograft tumor than the
MCC-DM1 ADC.
LINKER CHEMISTRY-LINKAGE TO ANTIBODY
Initially, the chemistry available for linkage to the polypeptide
of antibodies was limited to those natural amino acids that have
side-chains with available nucleophilic groups such as the ε-
NH2 of lysine and the sulfhydryl SH group of cysteine. Conju-
gation via lysine can involve a two-step process in which a linker
is attached to the mAb (mAb-L) followed by a second chemical
reaction of the linker with the cytotoxic drug molecule or can
involve a one-step reaction with a pre-formed L-D to form the
mAb-L-D. A typical IgG1 antibody has roughly 90 lysine res-
idues, of which approximately 30 can be modified under forc-
ing conditions (http://www.lifetechnologies.com/us/en/
home/references/molecular-probes-the-handbook.html).
Random conjugation utilizing lysine generates a heterogeneous
mixture of conjugate species (11). The mixture is generally
characterized by the average drug-to-antibody ratio, or DAR.
Typically, a DAR of 3–4 is targeted, as illustrated in Panel A of
Fig. 3. However, it must be noted that this heterogeneity is two-
fold since the drug can be conjugated to any number of the
approximate 30 available lysines. This produces a heteroge-
neous mixture of several subspecies some of which may have
altered antigen-binding properties leading to suboptimal po-
tency, solubility, stability, and/or pharmacokinetics.
Conjugation to the cysteines of an antibody differs in that
the cysteines are involved in intrachain and interchain disul-
fide bridges. Under controlled reduction conditions, the inter-
chain disulfide bonds can be reduced to create sulfhydryls
(Cys-SH) available for conjugation, while leaving the
intrachain disulfides intact. Since there are only 4 interchain
disulfide bridges in an IgG1, there are only 8 possible conju-
gation sites, thus conjugation via cysteine generates markedly
lower heterogeneity compared to lysine-based conjugation
and produces a mixture composed of even-numbered cytotox-
in-loaded species as depicted in Panel B of Fig. 3. Still, the
heterogeneity inherent with both of these types of conjugation
can cause challenges during the scale-up and production of
ADCs due to potential batch-to-batch variability.
A solution to the inherent heterogeneity of antibody-drug
conjugates has been to introduce engineered cysteines into the
sequence of the antibody such that only 1 or 2 conjugates can
be formed as demonstrated in Panel C. This work, pioneered
by Junutula et al., involved phage display for selection of reac-
tive thiols that do not alter antigen binding or function (12).
These engineered thio antibodies were termed THIOMAB
conjugates. The anti-MUC16 THIOMAB was shown to be
as efficacious as the traditional conjugate with approximately
half the drug dose and was better tolerated in rat and monkey
toxicity studies.
Fig. 2 Mechanism of action of
ADCs: The antibody portion of an
ADC hones onto a cell-surface
antigen that is ideally specific to a
cancer cell. Upon binding, the
ADC-antigen protein complex
becomes internalized into the
cancer cell. When the complex is
degraded, it releases the cytotoxin
which then binds to its target to
cause cancer cell apoptosis.
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RELEASE OF CYTOTOXIN
There are two families of linkers, cleavable and non-cleavable.
Cleavable linkers utilize an inherent property of a tumor cell
for selective release of the cytotoxin from the ADC. There are
three commonly used mechanisms: 1) protease-sensitivity, 2)
pH-sensitivity, and 3) glutathione-sensitivity. The protease-
sensitive strategy utilizes the dominant proteases found in a
tumor cell lysosome for recognition and cleavage of a specific
peptide sequence in the linker. Dubowchik and Firestone et al.
pioneered the discovery of the valine-citrulline (vc) dipeptide
as a intracellular cleavage mechanism by cathepsin B (13).
The acid-sensitivity strategy takes advantage of the lower pH
in the endosomal (pH = 5–6) and lysosomal (pH = 4.8) com-
partments, as compared to the cytosol (pH = 7.4), to trigger
hydrolysis of an acid labile group within the linker, such as a
hydrazone (14). The third release strategy exploits the higher
concentrations of intracellular glutathione than in the plasma.
Thus, linkers containing a disulfide bridge release the cytotox-
in upon reduction by glutathione. Non-cleavable linkers con-
tain no obvious release mechanism. This strategy relies on the
complete degradation of the antibody after internalization of
the ADC. As a consequence of this degradation, the linker will
carry an amino acid from the antibody. Below, linkers
employing these various release strategies will be discussed
for each cytotoxin class since the few linker-drug motifs that
have been successful have repeatedly been used for other
antibodies.
LINKER-CYTOTOXIN MOTIFS
The pioneering ADC,Mylotarg® (Gemtuzumab ozogamicin),
was approved in 2000. The construct of Mylotarg® consisted
of a relatively labile hydrazone linker with the cytotoxin,
calicheamicin. However, a confirmatory post-approval study
was stopped early due to safety concerns and a lack of clinical
benefit. It is believed that the heterogeneous nature of the
conjugate and hydrazone linker instability played a role in
the safety ofMylotarg® and it was voluntarily withdrawn from
the market in 2010. Interestingly, there are currently two clin-
ical candidates that utilize hydrazone constructs different from
Mylotarg®, the first, CMC-544 (Inotuzumab ozogamicin), is
calicheamicin-based and the second, milatuzumab-doxorubi-
cin, is doxorubicin derived. In the last several years, two ADCs
have been approved; this includes ADCETRIS®
(Brentuximab vedotin) in 2011 for relapsed Hodgkin lympho-
ma and Kadcyla® (Trastuzumab emtansine) in 2013 for
HER2+ breast cancer. ADCETRIS® utilizes a protease-
sensitive linker-drug motif discussed later under auristatins
and Kadcyla® uses a non-cleavable linker-drug motif to be
discussed under the maytansines section. In addition, there
are 40 ADCs at various stages of clinical development as of
December 2014 (see Electronic supplementary material).
CYSTEINE LINKERS
Of the 40 ADCs that are in clinical trials, only 34 have
disclosed the structures. The majority of these structures (24
out of 34) utilize attachment of the linker-drug directly to
cysteine of the antibody. In fact, all of these take advantage
of the excellent reactivity of maleimide with sulfhydryl groups.
There are two common maleimide-type l inkers :
maleimidocaproyl (mc) and maleimidomethyl cyclohexane-
1-carboxylate (abbreviated Bmcc^ in this review) (Fig. 4). All
of the auristatin-containing ADCs, both monomethyl
auristatin E (MMAE) and monomethyl auristatin F (MMAF),
utilize the Bmc^ linkage to the antibody. One negative aspect
of utilizing maleimide chemistry for cysteine linkage has been
its chemical instability in plasma, including a retro-Michael
reaction which results in premature loss of the drug-linker
from the ADC. Senter et al. realized that hydrolysis of the
thiosuccinimide ring prevented this elimination. Thus, this
Fig. 3 (11) Heterogeneity observed through different means of antibody-payload conjugation. Panel A depicts conjugation through lysines. Since approximately
30 of the 80 lysines on an IgG1 are available for conjugation, several species containing different drug-antibody ratios (DAR) are formed. Panel B depicts the
reduced hetereogeneity of conjugation through reduced disulfides. Panel C indicates that a DAR of 1 or 2 is obtained via attachment of the cytotoxin to engineered
cysteines
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group incorporated a basic amino functionality adjacent to
the maleimide to induce rapid hydrolysis at neutral pH. These
self-hydrolyzing maleimide-containing ADCs have shown im-
proved potency (15).
CYSTEINE-LINKER-AURISTATIN MOTIFS
Thirteen of the 18 disclosed auristatin-containing structures
utilize the Bvc-MMAE^ linker-drug combination (Table I).
Although abbreviated vc-MMAE, the construct is actually
better described as mc-vc-PABC-MMAE. This linker-
drug, mc-vc-PABC-MMAE, is conjugated to cysteine af-
ter reduction of the interchain cysteines of the antibody,
producing an ADC with a DAR of 4. The construct uti-
lizes a maleimidocaproyl (mc) spacer, a protease-sensitive
dipeptide, valine-citrulline (vc), a self-immolative spacer,
para-amino benzyloxycarbonyl (PABC), and the antimi-
totic agent, monomethyl auristatin E (MMAE) as
illustrated in Fig. 5. The purpose of the mc spacer is to
provide enough room so that the vc group can be recog-
nized by cathepsin B, which cleaves the citrulline-PABC
amide bond. The resultant PABC-substituted MMAE is
not a stable intermediate and spontaneously undergoes a
1,6-elimination with a loss of p-iminoquinone methide
and carbon dioxide (self-immolation) leaving MMAE as
the product. The optimization of this design was an evo-
lutionary process which entailed much experimentation
(16). This design was successfully used in ADCETRIS®,
an anti-CD30-vc-MMAE construct, for relapsed Hodgkin
lymphoma.
An analog of MMAE in which the terminal ephedrine
group in replaced by phenylalanine, termed monomethyl
auristatin F (MMAF), produced a Bvc-MMAF^ cAC10
ADC in which the cytotoxicity was >2200-fold more potent
than the corresponding free MMAF. This reduced inherent
cytotoxicity of the unconjugated, free drug, is presumably due
to the charged C-terminal carboxylate of phenylalanine that
Fig. 4 Maleimide chemistry has
been the mainstay for linkage to
cysteines. Two common variants
are the maleimidocaproyl (mc) and
maleimidomethyl cyclohexane-1-
carboxylate (mcc). Also illustrated is
the self-stabilizing maleimide
construct designed to prevent early
release of the cytotoxin via retro-
Michael reaction
Table I Clinical ADCs utilizing Bvc-MMAE^
Ph Originator Licensee (L)/
collaborator (C)
Common name Specificity target name Targeted disease
3 Seattle Genetics Celldex (L) CDX-011 anti-GPNMB breast cancer
2 Seattle Genetics Progenics anti-PSMA prostate
2 Seattle Genetics Genentech RG-7596 anti-CD79b NHL
2 Seattle Genetics Genentech RG-7593 anti-CD22 NHL
2 Seattle Genetics Genentech RG-7599 anti-NaPi2b ovarian cancer
1 Seattle Genetics SGN-LIV1A anti-Liv1 LIV1+ breast cancer
1 Seattle Genetics Agensys(C) ASG-22ME Nectin-4 solid tumors
1 Seattle Genetics Agensys(C) ASG-15ME SLTRK6 bladder cancer
1 Seattle Genetics Genentech RG-7450 anti-STEAP1 prostate
1 Seattle Genetics Genentech RG-7458 anti-MUC16 ovarian
1 Agensys AGS67E anti-CD37 NHL, CLL, AML
1 Seattle Genetics GenMab HuMax-TF anti-TF solid tumors
1 Seattle Genetics Takeda MLN-0264 anti-GCC gastrointestinal cancer
3530 Jain, Smith, Ghone and Tomczuk
impairs intracellular access in normal cells. Thus, this provides
the rationale for the observed larger therapeutic window for
cAC10-vc-MMAF than the corresponding cAC10-vc-MMAE
(17). However, the most unexpected finding was that the mc-
vc-PABC linker could be replaced with maleimidocaproyl
(mc), which is termed Bmc-MMAF^. This particular ADC
was equipotent to the one possessing a cleavable linker but
without an obvious release mechanism. Using radiolabelling,
it was demonstrated that mc-MMAF is released after mAb
degradation to produce the cysteine adduct as illustrated in
Fig. 6 (17). The therapeutic window for the cAC10-mc-
MMAF ADC is at least 3-fold higher than for cAC10-vc-
MMAF. Thus, there has been significant effort in utilizing this
simple linkage system and there are currently five disclosed
mc-MMAF ADCs in the clinic, all in phase 1, as shown in
Table II.
CYSTEINE-LINKER-PBD DIMER MOTIF
The pyrrolobenzodiazepines (PBD) are a class of naturally
occurring antitumor antibiotics that bind to the minor groove
of DNA (18). The dimerization of two PBD units by a suitable
spacer dramatically increases the ability of the dimer to cross-
link DNA via the N2 of guanine from opposing DNA strands
(19). There are two PBD dimer-containing ADCs in Phase 1
clinical trials, both from Seattle Genetics. They are SGN-
CD33A which is linked via an engineered-cysteine, termed
ec-mAb, to mc and a protease-cleavable, valine-alanine (va)
linker to an aniline on the PBD dimer (Fig. 7). SGN-CD33A is
being tested in acute myeloid leukemia (AML). The other
PBD dimer ADC, SGN-CD70A, is similarly linked to an
engineered cysteine and is being tested in non-Hodgkin Lym-
phoma (NHL) and renal cell carcinoma (RCC). It is notewor-
thy that both SGN-CD33A and SGN-CD70A represent the












SGN-CD70A anti-CD70 NHL & RCC
CYSTEINE-LINKER-DUOCARMYCIN MOTIF
Duocarmycins, which are DNA alkylating cytotoxins, have
been linked via a Bmc-like^ spacer to partially reduced
trastuzumab in SYD-985 (20). The mc is attached to a
protease-sensitive linker, valine-citrulline (vc), which is in-
turn linked to a PABC and further connected to a cyclization
module (CM) before forming a carbamate with the phenolic
group of a modified duocarmycin. Figure 8 depicts the pre-
sumed release mechanism of DUBA (DUocarmycin-
hydroxyBenzamide-Azaindole linker). Protease cleavage
followed by self-immolation of the PABC group via 1,6-elim-
ination and of the cyclization module group liberates the free
drug. The intermediate seco-DUBA is not a stable species and
Fig. 5 A common structure for
MMAE linkage has been the use of
Bmc^ attached to a protease
recognition sequence of valine-
citrulline (vc), which in turn is at-
tached to a para-amino benzyl al-
cohol (self-immolative moiety)
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undergoes a rearrangement with the formation of a cyclopro-








1 Synthon SYD985 anti-HER2 solid tumors
CYSTEINE-LINKER-SN38 MOTIF
Immunomedics has been utilizing SN-38, a metabolite of
irinotecan (a topoisomerase I inhibitor), as a cytotoxin. SN-
38 is about 3 orders of magnitude more potent than
irinotecan. SN-38 has been linked to two different mAbs,
the resultant ADCs are both in phase 2 clinical trials:
IMMU-130 (labetuzumab-SN38, anti-CEACAM5) is being
tested in colorectal cancer (CRC) and IMMU-132 (anti-
TROP-2) is being pursued in solid tumors (21, 22). Both
ADCs use a similar linker construct as shown in Fig. 9. The
linker construct consists of mcc-triazole spacer-PEG7-x-lysine-
PABC-SN-38. While the linker does not contain a protease-
sensitive moiety, it does contain an acid-sensitive carbonate
formed with the C-20 hydroxyl group of SN-38. Under
lysosomally relevant conditions of pH ~5, this construct has
a half-life of 10 h (23). It was also discovered that this C-20
attachment preserves the lactone which is a key feature for
bioactivity. The PEG7 spacer provided sufficient solubility.
With this particular linker, it was also determined that a high
DAR of about 6 molecules of drug per IgG was optimal. The







2 Immunomedics IMMU-130 anti-CEACAM5 CRC
2 Immunomedics IMMU-132 anti-TROP-2 solid tumors
CYSTEINE-LINKER-DOXORUBICIN MOTIF
Milatuzumab-doxorubicin (anti-CD74) utilizes a spacer other
than mc, while still relying on cysteine-maleimide chemistry.
Fig. 6 Construct of a mc-MMAF
ADC
Table II Clinical ADCs Utilizing Bmc-MMAF^
Ph Originator Licensee Common name Specificity target name Targeted disease
1 Agensys AGS-16M8F/16C3F anti-AGS-16 RCC
1 Seattle Genetics Pfizer PF-06263507 anti-5 T4 solid tumors
1 Seattle Genetics Abbvie ABT-414 anti-EGFR SC tumors & glioblastoma
1 GSK GSK2857916 anti-BCMA MM
1 Seattle Genetics SGN-CD19A anti-CD19 ALL & B-cell NHL
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In this motif, a maleimidomethyl cyclohexane-1-carboxyl hy-
drazide is reacted with doxorubicin to form a mcc-hydrazone
linked-doxorubicin which is then reacted with the reduced
cysteines (SH) on milatuzumab (Fig. 10). Milatuzumab-
doxorubicin is being pursued in Phase 1 studies for NHL
and chronic lymphocytic leukemia (CLL). Obviously, the















As previously mentioned, an IgG1 has 4 interchain disulfides
which are reduced to produce reactive sulfhydryl groups.
Using the maleimide chemistries outlined above produces
conjugation heterogeneity and destabilizes the higher order
structure of the IgG due to the loss of these interchain cross-
linkages (24). As an alternative, novel strategies are being pur-
sued which allow for rebridging of the reduced disulfide bonds
with reagents that carry the cytotoxin. Thus, both sulfhydryl
groups derived from a reduced disulfide bond are rebridged
by the reagent. PolyTherics has published work using a sul-
fone reagent which rebridges the disulfide with an intervening
Fig. 7 Construct of PBD dimer
ADCs. The mc-va-PBD dimer
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3-carbon bridge as shown in Panel A of Fig. 11 (25). In a
similar fashion, Igenica has a bis-reactive agent, a di-
thiopyridylmaleimide (DTM), which produces a 2-carbon
bridge as shown in Panel B of Fig. 11 (http://adc-summit.
com/uploads/files/2463_ADC_/David_Jackson.pdf). Both
of these reagents have the potential of producing a
homogeneous product with a DAR of 4. However, there are
currently no ADC clinical candidates which utilize these
reagents.
LYSINE LINKERS
Despite the inherent increased heterogeneity, there are 10
clinical candidates that still utilize the reactivity of the ε-
amino group of lysine—almost all involve acylation chemistry.
In most of these cases, the conjugation is carried out in a two-
step fashion. In the first step, a bi-functional reagent (contain-
ing amine- and thiol-reactive functional groups) is reacted
with available ε-amino groups of lysine (i.e., acylation). In
the second step, the cytotoxin-linker (which possesses a reac-
tive sulfhydryl) is attached to the available thiol-reactive group
introduced in step one. There are four types of lysine linkers
currently used in clinical candidates (Fig. 12): 1) SPDB disul-
fide, 2) MCC (maleimidomethyl cyclohexane-1-carboxylate),
3) sulfo-SPDB which adds a charged polar group and 4)
hydrazone (as used in CMC-544).
LINKER-MAYTANSINOID MOTIFS
The cytotoxic drug class known as maytansines has beenmod-
ified to contain a reactive sulfhydryl handle. Thus, 9 out of 10
of the lysine-linked clinical ADCs are maytansinoids
(Table III). Five of these candidates have a derivative known
as DM4 and the remaining four contain a derivative known as
DM1. The maytansinoid core of DM1 and DM4 is the same,
but the substitution adjacent to the sulfhydryl handle is differ-
ent, as illustrated in Fig. 13. It is important to note that
Kadcyla®, the ADC approved in 2013 for the treatment of
Fig. 9 mcc-triazole spacer-PEG7-
x-Lys-PABC-SN-38 motif
Fig. 10 Illustrates the use of mcc in
an acyl-hydrazone structure found
in Milatuzumab-Doxorubicin
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Her2+ breast cancer, is a MCC-DM1 construct. The conju-
gation is a two-step process which involves a conjugation of
the NHS-activated ester of the bifunctional linker, SMCC, to
trastuzumab followed by the reaction of the sulfhydryl from
DM1 with the maleimide. The manufacturing process has
been standardized to produce a Poisson distribution of 0 to
8 drugs per antibody with a DAR of 3.5. Approximately 70
sites out of 88 total lysines and four N-terminal amines have
been identified as participating in the attachment of MCC-
DM1 (26).
It was discovered that the unhindered disulfide-bond of
DM1 was too unstable in plasma leading to fast plasma clear-
ance with undetectable levels of ADC by day 3. An increase in
local steric hindrance by the addition of alpha-methyl groups
next to the disulfide provided the expected increase in plasma
stability. The construct possessing alpha gem-dimethyl groups
on the maytansinoid side (DM4) and one methyl group on the
antibody side was as stable as the non-cleavable linker, MCC-
DM1 (27). It is known that as the linker becomes more hydro-
phobic, aggregation become problematic. There have been
efforts to develop more soluble linkers for the maytansinoids.
Linkers containing the uncharged polyethylene glycol (PEG)
spacers and pendant sulfonate groups (such as sulfo-SPDB
shown in Fig. 12) have been evaluated. Aside from limiting
the formation of aggregates, the polarity of these spacers also
alter the interaction of the ADCs with permeability glycopro-
tein (Pgp) which is a major cause of multi-drug resistance
(MDR) by the tumor cells (28). In one study, an ADC using
a PEG4Mal linker with DM1 was markedly more effective in
eradicating MDR-expressing xenograft tumors than the ADC
Fig. 11 Panel A describes 3-carbon bridge by PolyTherics and Panel B describes 2-carbon bridge by Igenica
Fig. 12 Lysine linkers involve the
formation of amides with the ε-
amino group of lysine. The most
common linkers found in current
clinical candidates have been MCC
and SPDB, which are both un-
charged, lipophilic linkers. Recent
research has focused on the intro-
duction of charged, hydrophilic
groups, like sulfo-SPDB to minimize
aggregation tendencies
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with theMCC-DM1 linker (10). In a similar manner, an ADC
using the sulfo-SPDB linker with DM4 was considerably more
potent against an MDR expressing cell line with an IC50=7–
20 pM vs >3000 pM for the ADCs with SPDB or MCC
linkers (28).
To reiterate, linkers can be classified as cleavable or
non-cleavable. Cleavable linkers possess functionalities
susceptible to degradation through lysosomal processes
(protease-sensitive, acid-sensitive, and reduction-sensi-
tive). ADCs made with non-cleavable linkers, in com-
parison, have extended plasma half-life which is a desir-
able attribute. The activity of these non-cleavable
linkers in the tumor cells relies on the degradation of
the total antibody, ultimately releasing an amino-acid-
linker-cytotoxin construct. Examples of well-established
non-cleavable linkers include maleimidocaproyl (mc),
used with MMAF, and MCC, often used with DM1
conjugates.
LINKER-CALICHEAMICIN MOTIF








Pfizer CMC-544 anti-CD22 ALL,
DLBCL
Table III Clinical ADCs Utilizing MCC-DM1 or SPDB-DM4
Phase Originator Licensee (L)/
collaborator(C)
Common name Specificity target name Targeted disease
MCC-DM1 ADCs
1 ImmunoGen IMGN 289 anti-EGFR NSCLC, SCCHN, SC NSCLC
1 ImmunoGen IMGN 529 NHL/CLL
1 ImmunoGen Amgen AMG 595 anti-EGFRvIII glioblastoma
1 ImmunoGen Amgen AMG 172 anti-CD27L
SPDB-DM4 ADCs
2 ImmunoGen SAR3419 anti-CD19 diffuse large B-cell lymphoma
2a ImmunoGen IMGN 853 anti-FRa
2 ImmunoGen Biotest BT-062 anti-CD138 MM
1 ImmunoGen Sanofi SAR 566658 anti-CA6 solid tumors
1 ImmunoGen Bayer BAY 94-9343 anti-mesothelin
a IMGN 853 uses sulfo-SPDB linker
Fig. 13 MCC-DM1 and SPDB-
DM4 motifs used in the clinical
candidates listed in Table IV
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CMC-544 (Inotuzumab ozogamicin) is in phase 3 clinical
trials for acute lymphoblastic leukemia and diffuse large B-cell
lymphoma. CMC-544 consists of a humanized IgG4 anti-
CD22 an t ibody cova l en t l y l i nked v ia an 4 - (4 -
acetylphenoxy)butanoic acid (AcBut) to an acyl hydrazide de-
rivative of γ-calicheamicin as shown in Fig. 14 (29). The acyl
hydrazide is produced by the displacement of the
methyltrisulfide moiety of γ-calicheamicin with 3-mercapto-
3-methylbutyryl hydrazide, termed N-acetyl γ-calicheamicin
dimethyl hydrazide. It is worth noting that this linker construct
was also utilized in Mylotarg®. Once internalized to the lyso-
some of the tumor cell, the payload undergoes a two-stage
activation process. First, the acid-sensitive hydrazone is hydro-
lyzed and the aryl tetra saccharide portion of the drug binds to
the minor groove of DNA (30). Next is the reduction of the
disulfide bond by glutathione, allowing the sulfhydryl
intermediate to cyclize onto the enediyne core structure to
generate a reactive para-phenylene diradical species that ab-
stracts hydrogen from the phosphodiester backbone to pro-
duce double-strand DNA breaks leading to cell death (31).
SITE-SPECIFIC ANTIBODY DRUG CONJUGATES
The inherent chemical and biological issues of heterogeneous
mixtures have led to efforts directed toward achieving site-
specific conjugation. Site-specific conjugation enables the at-
tachment of a specific number of conjugated drugs at defined
sites on the antibody, leading to a homogeneous product with
well-defined characteristics. The methodologies can be cate-
gorized under the heading of 1) genetic engineering of cysteine
or seleno cysteine residues, 2) incorporation of non-natural
amino acids (nnAA) possessing reactive handles (by either ge-
netic engineering or enzymaticmodification) and 3) enzymatic
modification (11). These site specific methodologies are listed
in Table IV.
Conjugation through engineered cysteine (or seleno cyste-
ines) utilizes standard cysteine linker chemistry previously de-
scribed, such as reaction with maleimide or bromoacetamide
moieties. However, other non-natural amino acids (nnAA)
have been produced via enzymatic modification of the fully
constructed mAb. For example, antibodies containing a reac-
tive aldehyde handle have been produced using formylglycine
generating enzyme (FGE), an enzyme recognizing the se-
quence CxPxR and oxidizing the cysteine residue to form
formylglycine in the pioneering work of Bertozzi et al. (35).
The FGE/aldehyde tag technology together with novel
bioconjugation chemistry has been termed SMARTag (Spe-
cific Modifiable Aldehyde Recombinant Tag) technology. In
this technology, the newly generated aldehydes are reacted
Fig. 14 Construct of AcBut-N-Ac-γ-calicheamicin. CMC-544 utilizes an
AcBut (4-(4-acetylphenoxy)butanoic acid) linked to an acyl hydrazide deriva-
tive of γ-calicheamicin. The acyl hydrazide is produced by the displacement of
the methyltrisulfide moiety of γ-calicheamicin with 3-mercapto-3-
methylbutyryl hydrazide, termed N-acetyl γ-calicheamicin dimethyl
hydrazide.
Table IV Site-Specific Conjugation Technologies
Description Methodology DAR Conjugation chemistry Companies Ref





Seleno cysteine 2 Maleimide NCI (33)
p-AcPhe 2 or 4 Oxime Allozyne, Ambrx (34)
FGE (formylglycine
generating enzyme)
2 or 4 Oxime, Pictet-Spengler Catalent Pharma Solutions (35, 36)
Azide or alkynyl nnAA
or glycan
1 to 2 Click chemistry Sutro, Allozyne, Synaffix (37)
Enzymatic Glycotransferase 2 2-keto-Gal NCI (38)
BTG (bacterial
transglutaminase)




Sortase A 2 or 4 Hydrolysis of Thr-Gly in
LPxTG motif
NBE Therapeutics http://www.nbe-therapeutics.com
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with indole nucleophiles in a variation of the classical Pictet-
Spengler reaction. In the first approach, an indole carrying a
hydroxylamine reacts with the aldehyde to produce an inter-
mediate oxyiminium ion which undergoes intramolecular C-
C bond formation to form a hydrolytically stable,
oxacarboline product (36). The second approach utilizes the
hydrazino-Pictet-Spengler (HIPS) reaction to form hydrolyti-
cally stable conjugates (Fig. 15). ADCs generated using HIPS
chemistry shows >90% stability in human plasma after 7 days
at 37°C, regardless of the conjugation site. In addition to
producing a very stable C-C bond, the HIPS reaction takes
place at neutral or near neutral pH as opposed to the acidic
conditions required for typical oxime chemistry. The ability to
generate stable bioconjugates using mild, near physiological
pH conditions offers numerous advantages over other existing
bioconjugation methods (35).
An alternative to enzymatic modification is to use site-
specific incorporation of non-natural amino acid (nnAAs) with
chemical side chains that are compatible with bio-orthogonal
conjugation chemistry. For example, p-acetylphenylalanine
(pAcPhe), which contains a carbonyl (ketone) as a reactive
handle, has been site-specifically incorporated into
trastuzumab. The ketone can then react with a drug contain-
ing an alkoxy-amine to produce an oxime (34). Other nnAA
can be incorporated via translation as the antibody is
expressed. This strategy provides controlled sites for conjuga-
tion of the cytotoxic drug. A group at Scripps, led by Peter
Schultz, has pioneered the encoding of reactive nnAAs pro-
teins by engineering new cell lines or protein expression that
have the transcriptional machinery to place a nnAAwhere it is
required (41). An azide containing nnAA, such as para-
azidomethyl-L-phenylalanine (pAMF), can be incorporated
into the sequence of an antibody, making conjugation via
strain-promoted azide-alkyne cycloaddition (SPAAC)
copper-free click chemistry a possibility (Fig. 16).
Zimmerman, for example, has used this strategy to conjugate
monomethylauristatin F (MMAF) to an engineered
trastuzamab derivative (37). The resultant ADC displayed
high potency in in vitro cell cytotoxicity assays.
SUMMARY
The list of ADCs in the clinic continues to grow, bol-
stered by the success of ADCETRIS® and Kadcyla®.
ADCETRIS® is conjugated to cysteines made available
through the reduction of interchain disulfide bridges
and contains a protease-sensitive linker, mc-vc-PABC-
MMAE, a motif that is utilized in 13 clinical candi-
dates. The additional 11 ADC clinical candidates that
conjugate to cysteine utilize maleimide chemistry either
to mc or mcc. The remaining 10 candidates with known
linker-cytotoxin constructs utilize acylation chemistry to
surface lysines of the antibody. Kadcyla® uses a non-
cleavable MCC-DM1 (thioether) linker to lysine, a motif
that is found in four clinical candidates. An additional
five maytansinoid clinical candidates utilize the disulfide
linker, SPDB or sulfo-SPDB. The calicheamicin ADC
has a AcBut acyl hydrazone-disulfide linker.
Fig. 15 Conjugation based on the production of an aldehyde containing antibody using formylglycine generating enzyme (FGE), an enzyme recognizing the
sequence CxPxR and oxidizing the cysteine residue to form formylglycine. The aldehyde is reacted with a cytotoxin-linked indole hydrazine to form a
hydrolytically-stable conjugate (Hydrazino-Pictet-Spengler Reaction).
Fig. 16 Antibody engineered to contain an non-natural amino acid containing an azido group which can undergo click chemistry with an alkyne-containing linker-
drug.
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The advantage of lysine-based conjugations is that
surface lysines are utilized with no alteration of the an-
tibody structure. However, the disadvantage is that
there are approximately 30 available lysines for conju-
gation resulting in ADC heterogeneity. The counter ef-
forts have focused on cysteine conjugation because of its
reduced heterogeneity due to the reduction of only 4
interchain disulfides. However, this reduction of the an-
tibody may affect overall ADC-construct stability. In
turn, efforts are now focused on the development of
bifunctional sulfhydryl linkers that can potentially im-
prove ADC stability.
Significant research efforts are now being directed toward
the production of discrete, homogeneous ADC products, via
site-specific conjugation. Site-specific conjugation technolo-
gies either rely on genetic re-engineering to introduce a dis-
crete, available cysteine or a non-natural amino acid with an
orthogonally-reactive functional group handle such as an al-
dehyde, ketone, azido, or alkynyl tag. Another site-specific
conjugation strategy has been selective modification of the
antibody by enzymes such as FGE, BTG, sortase, or
glycotransferase. These site-specific approaches not only in-
crease the homogeneity of ADCs, but also enable novel bio-
orthogonal chemistries that utilize reactivemoieties other than
thiol from cysteine or amine from lysine. This broadens the
diversity of linkers that can be utilized which will lead to better
linker design in future generations of ADCs.
Open Access This article is distributed under the terms of
the Creative Commons Attribution License which permits
any use, distribution, and reproduction in any medium, pro-
vided the original author(s) and the source are credited.
REFERENCES
1. Schwartz RS. Paul Ehrlich’s magic bullets. N Engl J Med. 2004;350:
1079–80.
2. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang
R, et al. Phase I studies of AVE9633, an anti-CD33 antibody-
maytansinoid conjugate, in adult patients with relapsed/refractory
acute myeloid leukemia. Investig New Drugs. 2012;30:1121–31.
3. Lonberg N. Human antibodies from transgenic animals. Nat
Biotechnol. 2005;23:1117–25.
4. Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges
and potential. Clin Cancer Res. 2011;17:6389–97.
5. Trail PA. Antibody drug conjugates as cancer therapeutics.
Antibodies. 2013;2:113–29.
6. Lambert JM. Drug-conjugated antibodies for the treatment of can-
cer. Br J Clin Pharmacol. 2012;76:248–62.
7. Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder
GM, Vite GD, et al. Drug Discov Today. 2014;19:869–81.
8. Jarvis LM. Rethinking antibody-drug conjugates. Chem Eng News.
2012;90:12–8.
9. Joubert MK, HokomM, Eakin C, Zhou L, Despande M, Baker MP,
et al. Highly aggregated antibody therapeutics can enhance the
in vitro innate and late-stage T-cell immune responses. J Biol
Chem. 2012;287:25266–79.
10. Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H,
Maloney EK, et al. Antibody-maytansinoid conjugates designed to
bypass multidrug resistance. Cancer Res. 2010;70:2528–37.
11. Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific
antibody drug conjugates for cancer therapy. mAbs. 2014;6:1–12.
12. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al.
Site-specific conjugation of a cytotoxic drug to an antibody improves
the therapeutic index. Nat Biotechnol. 2008;26:925–32.
13. Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ,
Mosure K, et al. Cathepsin B-Labile dipeptide linkers for lysosomal
release of doxorubicin from internalizing immunoconjugates: model
studies of enzymatic drug release and antigen-specific in vitro antican-
cer activity. Bioconjug Chem. 2002;13:855–69.
14. Ritchie M, Tchistiakova L, Scott N. Implications of receptor-
mediated endocytosis and intracellular trafficking dynamics in the
development of antibody drug conjugates. mAbs. 2013;5:13–21.
15. Lyon RP, Setter JR, Bovee TD, Doronina SO, Hunter JH, Anderson
ME, et al. Self-hydrolyzing maleimides improve the stability and
pharmacological properties of antibody-drug conjugates. Nat
Biotechnol. 2014;32:1059–62.
16. Senter PD, Sievers EL. The discovery and development of
brentuximab vedotin for use in relapsed Hodgkin lymphoma and
systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30:
631–7.
17. Dorinina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC,
Meyer DL, et al. Enhanced activity of monomethylauristatin F
through monoclonal antibody delivery: effects of linker technology
on efficacy and toxicity. Bioconjug Chem. 2006;17:114–24.
18. Antonow D, Thurston DE. Synthesis of DNA-interactive pyrrolo[2,
1-c][1,4]benzodiazepines (PBDs). Chem Rev. 2011;111:2815–64.
19. Hartley JA, Hamaguchi A, Suggitt M, Gregson SJ, Thurston DE,
Howard PW. DNA interstrand cross-linking and in vivo antitumor
activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer
SG2057. Investig New Drugs. 2012;30:950–8.
20. Dokter W, Ubink R, van der Lee M, van der Vleuten M, van
Acgterberg T, Jacobs D, et al. Impressive efficacy and safety profile
of a novel generation duocarmycin-based HER2-targeting ADC.
Am Assoc Cancer Res. 2014; Poster #2651, San Diego, CA.
21. Dotan E, Berlin JD, Starodub AN, GuarinoMJ, Cohen SJ, Maliakal
PP, et al. Activity of IMMU-130 anti-CEACAM5-SN-38 antibody-
drug conjugate (ADC) on metastatic colorectal cancer (mCRC) hav-
ing relapsed after CPT-11: Phase I study. J Clin Oncol. 2014; 32(5s):
abst 3106.
22. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg
DM. Humanized Anti-TROP-2 IgG-SN-38 conjugate for effective
treatment of diverse epithelial cancers: preclinical studies in human
cancer xenograft models and monkeys. Clin Cancer Res. 2011;17:
3157–69.
23. Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV,
Goldenberg DM. Milatuzumab-SN-38 conjugates for the treatment
of CD74+ cancers. Mol Cancer Ther. 2013;12:968–78.
24. Guo J, Kumar S, Prashad A, Starkey J, Singh SK. Assessment of
physical stability of an antibody drug conjugate by higher order
structure analysis: impact of thiol-maleimide chemistry. Pharm Res.
2014;31:1710–23.
25. Badescu G, Bryant P, Bird M, Henseleit K, Swierkosz J, Parekh V,
et al. Bridging disulfides for stable and defined antibody drug conju-
gates. Bioconjug Chem. 2014;25:1124–36.
26. KimMT, Chen Y,Marhoul J, Jacobson F. Statistical modeling of the
drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-
linked antibody drug conjugate. Bioconjug Chem. 2014;25:1223–32.
27. Phillips GDL, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E,
et al. TargetingHER2-positive breast cancer with trastuzumab-DM1,
an antibody-drug conjugate. Cancer Res. 2008;68:9280–90.
Current ADC Linker Chemistry 3539
28. Zhao RY, Wilheim SD, Audette C, Jones G, Leece BA, Lazar AC,
et al. Synthesis and evaluation of hydrophilic linkers for antibody-
maytansinoid conjugates. J Med Chem. 2011;54:3603–23.
29. DiJoseph JF, Khandke K, Dougher MM, Evans DY, Armellino DC,
Hamann PR, et al. CMC-544 (inotuzumab ozogamicin): a CD22-
targeted immunoconjugate of calicheamicin. Hematol Meet Rep.
2008;2:74–7.
30. Walker S, Landovitz R, Ding WD, Ellestad GA, Kahne D. Cleavage
behavior of calicheamicin gamma 1 and calicheamicin T. Proc Natl
Acad Sci U S A. 1992;89:4608–12.
31. Prokop A, Wrasidlo W, Lode H, Herold R, Lang F, Henze G, et al.
Induction of apoptosis by enediyne antibiotic calicheamicin ϑII pro-
ceeds through a caspase-mediated mitochondrial amplication loop in
an entirely Bax-dependent manner. Oncogene. 2003;22:9107–20.
32. Junutula JR, Flagella KM,GrahamRA, Parsons KL, Ha E, Raab H,
et al. Engineered thio-trastuzumab-DM1 conjugate with an improved
therapeutic index to target human epidermal growth factor receptor
2-positive breast cancer. Clin Cancer Res. 2010;16:4769–78.
33. Hofer T, Skeffington LR, Chapman CM, Rader C. Molecularly
defined antibody conjugation through a selenocysteine interface.
Biochemistry. 2009;48:12047–57.
34. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane
SA, et al. Synthesis of site-specific antibody-drug conjugates using
unnatural amino acids. Proc Natl Acad Sci U S A. 2012;109:
16101–6.
35. Agarwal P, van der Weijden J, Sletten EM, Rabuka D, Bertozzi CR.
A Pictet-Spengler ligation for protein chemical modification. Proc
Natl Acad Sci U S A. 2013;110:46–51.
36. Agarwal P, Kudirka R, Albers AE, Barfield RM, deHart GW,Drake
PM, et al. Hydrazino-Pictet-Spengler ligation as a biocompatible
method for the generation of stable protein conjugates. Bioconjug
Chem. 2013;24:846–51.
37. Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ,
Madlansacay MR, et al. Production of site-specific antibody-drug
conjugates using optimized non-natural amino acids in a cell-free
expression system. Bioconjug Chem. 2014;25:351–61.
38. Boeggeman E, Ramakrishnan B, Pasek M, Manzoni M, Puri A,
Loomis KH, et al. Site specific conjugation of fluoroprobes to the
remodeled Fc N-glycans of monoclonal antibodies using mutant gly-
cosyltransferases: application for cell-surface antigen detection.
Bioconjug Chem. 2009;20:1228–36.
39. Farias SE, Strop P, Delaria K, Casas MG, Dorywalska M, Shelton
DL, et al. Mass spectrometric characterization of transglutaminase
based site-specific antibody-drug conjugate. Bioconjug Chem.
2014;25:240–50.
40. Strop P. Versatility of microbial transglutaminase. Bioconjug Chem.
2014;25:855–62.
41. Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, et al. A
general approach to site-specific antibody drug conjugates. Proc
Natl Acad Sci U S A. 2014;111:1766–71.
3540 Jain, Smith, Ghone and Tomczuk
